Objective: To investigate the clinical value of serum IL-6,CA724 and VEGF in gastric cancer patients. Methods:The serum levels of IL-6,CA724 and VEGF were detected with ELISA in 40 healthy subjects and 80 patients with gastric cancer. Results:The levels of three kinds of tumor markers in gastric cancer patients were obviously higher than those in the control group (IL:149.62 ± 43.00 vs 48.12 ± 28.02 ng/ml,CA724:15.29 ± 3.64 vs 4.53 ± 3.47 U/ml,VEGF:212.78 ± 125.61 vs 64.8 6±17.67 pg/ml,respectively,P < 0.01). Sensitivity of detection was improved when they were combined. The positive rate of IL-6,CA724 and VEGF in combination was 76.3%,which was significantly higher than that of single marker (33.8%,43.8% and 52.5%,respectively). The values of IL-6,CA724 and VEGF were also higher in gastric cancer patients with liver metastasis than those without such metastasis(168.43 ± 54.03 vs 130.81 ± 10.00 ng/ml,16.20 ± 4.57 vs 14.39 ± 2.05 U/ml,289.47 ± 140.61 vs 136.09 ± 11.22 pg/ml,P < 0.05). The positive rates of IL-6,CA724 and VEGF in gastric cancer patients with liver metastasis were remarkably higher than those in gastric cancer patients without liver metastasis(50.0% vs 17.5%,P < 0.05;55.0% vs 32.5%,P > 0.05;65.0% vs 40.0%,P > 0.05). Conclusion:The results suggested that the determination of serum IL-6,CA724 and VEGF is valuable for the diagnosis of gastric cancer and liver metastasis. The diagnostic value can be enhanced by detection of IL-6,CA724 and VEGF in combination.